Skip to main content

Table 1 Patient characteristics and comparison between survivors and non-survivors

From: Prognostic irrelevance of plaque vulnerability following plaque sealing in high-risk patients with type 2 diabetes: an optical coherence tomography study

  Study population Survivors Non-survivors
n = 81 n = 57 n = 24 p
Age (years) 69.6 ± 7.7 67.8 ± 7.8 74.0 ± 5.6 0.001
Sex (male, n, %) 54 (66.7) 39 (68.4) 16 (66.7) 0.606
ACS at presentation (n, %) 27 (33.3) 19 (33.3) 8 (33.3) 1.000
CV risk profile
 BMI (kg/m2) 30.7 ± 5.4 31.4 ± 5.5 28.9 ± 3.9 0.050
 Waist circumference (cm) 107.6 ± 13.2 108.2 ± 14.4 106.3 ± 9.8 0.562
 Hypertension (n, %) 70 (86.4) 50 (87.7) 20 (83.3) 0.599
 Hyperlipidemia (n, %) 58 (71.6) 42 (73.7) 16 (66.7) 0.522
 Total cholesterol (mg/dl) 190.0 ± 43.1 190.0 ± 43.1 190.0 ± 43.1 0.407
 LDL-c (mg/dl) 117.0 ± 35.1 115.1 ± 34.4 121.7 ± 37.2 0.450
 HDL-c (mg/dl) 43.3 ± 10.8 41.9 ± 9.5 46.7 ± 13.0 0.066
 Triglycerides (mg/dl) 173.1 ± 75.8 175.9 ± 78.0 166.7 ± 71.6 0.623
 Active smoking (n, %) 17 (21.0) 12 (21.1) 5 (20.8) 0.982
 Pack years (py) 19.3 ± 21.8 19.5 ± 23.0 18.7 ± 19.1 0.879
 Family history of CAD (n, %) 37 (45.7) 31 (54.4) 6 (25.0) 0.015
 Previous CAD (n, %) 30 (37.0) 18 (31.6) 12 (50.0) 0.117
 Previous PCI (n, %) 24 (29.6) 14 (24.6) 10 (41.7) 0.124
 Previous CABG (n, %) 2 (2.5) 1 (1.8) 1 (4.2) 0.523
 hsCRP (mg/dl) 13.6 ± 22.5 12.4 ± 23.1 16.6 ± 21.1 0.448
 GFR (mg/dl/1.73 m2) 58.8 ± 5.2 59.5 ± 3.8 57.1 ± 7.3 0.136
Other comorbidities
 COPD (n, %) 11 (13.6) 7 (12.3) 4 (16.7) 0.599
Diabetes severity and therapy
 Diabetes duration (years) 11.1 ± 10.0 10.3 ± 9.9 13.1 ± 9.9 0.250
 Diabetic polyneuropathy (n, %) 23 (28.4) 12 (21.1) 11 (45.8) 0.024
 Diabetic retinopathy (n, %) 14 (17.3) 8 (14.0) 6 (25.0) 0.233
 HbA1c (%) 7.1 ± 1.0 7.0 ± 1.0 7.3 ± 1.0 0.155
 Insulin (n,%) 34 (42.0) 18 (31.6) 16 (66.7) 0.003
 Metformin (n,%) 52 (64.2) 40 (71.4) 12 (50.0) 0.066
 Sulfonylamides (n, %) 17 (21.0) 13 (22.8) 4 (16.7) 0.535
 Incretins (n, %) 15 (18.5) 8 (14.0) 7 (29.2) 0.109
Other relevant medication
 Aspirin (n, %) 77 (95.1) 54 (94.7) 23 (95.8) 0.835
 Statin (n, %) 54 (66.6) 40 (71.4) 14 (58.4) 0.137
 ACE or ARBi (n, %) 58 (71.6) 42 (76.4) 16 (66.7) 0.370
 Beta-blocker (n, %) 62 (76.5) 46 (80.7) 16 (66.7) 0.173
  1. ACS acute coronary syndrome, BMI body mass index, CAD coronary artery disease, PCI percutaneous coronary intervention, CABG coronary artery bypass graft, GFR glomerular filtration rate, COPD chronic obstructive pulmonary disease, ACE angiotensin converting enzyme, ARB angiotensin receptor blocker